FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.
EJNMMI Res
; 2(1): 22, 2012 May 31.
Article
em En
| MEDLINE
| ID: mdl-22651703
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article